Alexion Pharmaceuticals Given New $138.00 Price Target at Stifel Nicolaus (ALXN)
Equities researchers at Stifel Nicolaus lifted their target price on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $131.00 to $138.00 in a research report issued on Friday, AnalystRatings.NET reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 18.25% from the company’s current price.
Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 4.39% during mid-day trading on Friday, hitting $121.828. The stock had a trading volume of 838,422 shares. Alexion Pharmaceuticals has a 52 week low of $81.82 and a 52 week high of $125.65. The stock’s 50-day moving average is $111.0 and its 200-day moving average is $100.2. The company has a market cap of $23.824 billion and a price-to-earnings ratio of 66.53.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, October 24th. The company reported $0.83 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.79 by $0.04. The company had revenue of $400.40 million for the quarter, compared to the consensus estimate of $395.10 million. During the same quarter in the prior year, the company posted $0.60 earnings per share. The company’s quarterly revenue was up 36.1% on a year-over-year basis. Analysts expect that Alexion Pharmaceuticals will post $3.03 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, October 18th. They now have a $133.00 price target on the stock. Separately, analysts at Goldman Sachs Group Inc. raised their price target on shares of Alexion Pharmaceuticals from $122.00 to $139.00 in a research note to investors on Wednesday, September 18th. They now have a “hold” rating on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $118.73.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.